PRINCETON, N.J. — UroGen Pharma Ltd., a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced a licensing agreement with MEDAC GmbH to develop a next-generation novel mitomycin-based formulation for urothelial cancers. UGN-103, UroGen’s RTGel® technology combined with medac’s licensed mitomycin, is a...
treatment News
Orphan Therapeutics, LLC and Ikaria Holdings, Inc announced that the US Food and Drug Administration (FDA) has accepted the final section of the New Drug Application (NDA) filing seeking marketing approval for Lucassin (terlipressin for injection) for the treatment of hepatorenal syndrome (HRS) Type-1. The filing was completed on May...
Basel, Switzerland – Sandoz, a global leader in biosimilar and generic medicines, today announced that the US Supreme Court has denied its petition to review the Federal Circuit’s July 2020 decision concerning the Sandoz biosimilar Erelzi® (etanercept-szzs) for reference medicine Enbrel®* (etanercept). The Federal Circuit previously ruled against Sandoz in...
Philadelphia, Pennsylvania – In the retinas of human eyes, the cones are photoreceptor cells responsible for color vision, daylight vision, and the perception of small details. As vision scientists from the Division of Experimental Retinal Therapies at the University of Pennsylvania School of Veterinary Medicine, Gustavo D. Aguirre and William A. Beltran have been working for...
Hong Kong – A crucial player in genomic integrity maintenance, DNA Polymerase Theta (Polθ) provides a potential synthetic lethal relationship in BRCA-deficient tumors, which are particularly prevalent in certain tumor types including triple-negative breast cancers (TNBC) and ovarian cancers. In fact, BRCA-deficient tumors account for 11-16% of TNBC cases, and...
SAN ANTONIO, TX – A drug developed at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has been shown to extend survival for patients with glioblastoma, the most common primary brain tumor in adults. Results of a trial led by the university revealed that...
SALT LAKE CITY, Utah — While many babies are born without issues on a daily basis, there are quite a few who are born early and with some complications. Those babies end up in the Neonatal Intensive Care Unit (NICU), which is where Dr. Sabrina Malone Jenkins works. The Neonatologist...
EL PASO, Texas — Researchers at The University of Texas at El Paso are developing a new therapeutic approach that uses nanoparticles for the treatment of skin and pulmonary fibrosis, conditions that can result in severe damage to the body’s tissues. Md Nurunnabi, Ph.D., is an associate professor in UTEP’s...
Houston, TX – A medication that appeared to stabilize the function and shape of red blood cells in an earlier study for patients with sickle cell disease is now part of a Phase III clinical trial that is open for enrollment at UTHealth Houston. The trial, led locally by Modupe Idowu,...
NEWARK, Delaware — Uvax Bio, LLC, a privately held, clinical-stage vaccine company utilizing rational and computational biology to design and deliver novel 1c-SApNP® protein-based vaccines, today announced the first participant has been dosed in a Phase 1 clinical trial evaluating the Company’s HIV-1 vaccine candidates, UVAX-1107 and UVAX-1197, in healthy...